KMITL

Permanent URI for this communityhttps://dspace.kmitl.ac.th/handle/kmitl/1

Browse

Settings

Subject: search.filters.subject.Helicobacter pylori

Search Results

Now showing 1 - 2 of 2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    A study on the anti-Helicobacter pylori activity of three medicinal plant crude extracts from Cannabis sativa, Mitragyna speciosa and Phyllanthus emblica
    (2026-05-01)
    Khruethuen, S.
    ;
    Pilasombut, P.
    ;
    Woraprayote, W.
    ;
    Janyaphisan, T.
    ;
    Pumpuang, L.
    In the present study, medicinal plant crude extracts were prepared from cannabis (Cannabis sativa), kratom (Mitragyna speciosa) and Indian gooseberry (Phyllanthus emblica) using four different solvents including ethanol, methanol, isopropanol, and water. The methanolic crude extracts had the highest weight and percentage yield, whereas the aqueous crude extracts exhibited the lowest values. The antimicrobial activity of these extracts against three Helicobacter pylori strains (ATCC 43504, 2888, and BK364) was evaluated using the spot-on-lawn method. The obtained results indicated that all medicinal plant crude extracts had an inhibitory effect against all tested H. pylori strains. The methanolic and ethanolic extracts of Cannabis sativa inhibited H. pylori strains ATCC 43504, 2888, and BK364 at the minimum inhibitory concentration (MIC) values ranging from 0.02-0.05 mg/mL. Additionally, a synergistic effect between Cannabis sativa, Mitragyna speciosa, and Phyllanthus emblica was investigated using the checkerboard assay. The synergistic interaction was observed between the Cannabis sativa, Mitragyna speciosa, and Phyllanthus emblica extracts, with a fractional inhibitory concentration index (FICI) of 2, indicating an indifferent effect when combined. Furthermore, the scanning electron microscopy (SEM) investigation revealed that the H. pylori cells were damaged after treatment with methanolic crude extracts of cannabis for 120 minutes.
      1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Lactic acid bacteria in the gastrointestinal tract: Anti-helicobacter pylori
    (2024-06-03)
    Techo, Sujitra
    ;
    Kingkaew, Engkarat
    ;
    Tanasupawat, Somboon
    Numerous bacterial species have been found throughout the human GI tract, which consists of the oral cavity, stomach, intestine, and colon. Lactic acid bacteria (LAB), including Lactobacillus (L. ) acidophilus, L. salivarius, L. johnsonii, L. crispatus, L. casei, L. paracasei, L. rhamnosus, L. reuteri, L. oris, L. vaginalis, L. gasseri, L. plantarum, L. buchneri, L. mali, L. ruminis, L. delbrueckii, L. sakei, L. fermentum, L. helviticus, and L. brevis ; Streptococcus ( S. ) salivarius, S. pneumonia, S. mitis, S. oralis, S. parasanguinis, S. anginosus, S. constellatus, S. caprinus, and S. mutans ; Leuconostoc (Ln. ) mesenteroides and Ln. argentinum ; Lactococcus (Lc.) lactis; and Enterococcus (En. ) strains, are distributed throughout the human GI tract. The bacterial microbiota in humans changes when infected with Helicobacter (H. ) pylori. Moreover, antibiotics and proton pump inhibitors (PPIs) used in the regimen influence microbial microbiota. However, alteration of bacterial diversity is rather complicated and has conflicting effects. To maintain microbial balance in the GI tract, several studies have used probiotics as adjunctive therapy to reduce the number of H. pylori in infected humans, replacing antibiotics alone. Probiotics have shown a higher eradication rate of H. pylori when compared with antibiotics alone. Bacteriocin production by LAB is one of the interesting mechanisms that can inhibit the growth of H. pylori. Bacteriocins and bacteriocin-like substances exhibiting antibacterial properties against H. pylori have been reported. These active peptides could be exploited to develop novel therapeutics for treating H. pylori infection.